Regulatory climate shifts could redefine "ocgn stock forecast 2025" dynamics; faster FDA review pathways or international approvals might bring valuation upside sooner than baseline models predict. Yet, in contrast to these new revenues, investors should be mindful that if late-stage trials were to experience setbacks or delays ... Not all analysts were so bearish, however. Following WHO approval in November 2021, Robert LeBoyer of Noble Financial reiterated his buy rating on Ocugen stock and maintained a price target of $15, representing a 56.41% upside on the price on the day of the report. Hedge fund participation in "ocgn stock forecast 2025" scenarios is minimal but increasing. Quarterly 13F filings indicate selective accumulation, possibly positioning for biotech sector rallies driven by policy or innovation catalysts.